Johnson & Johnson (NYSE:JNJ) Shares Sold by First County Bank CT

First County Bank CT lessened its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,788 shares of the company’s stock after selling 213 shares during the quarter. Johnson & Johnson accounts for about 0.9% of First County Bank CT’s holdings, making the stock its 26th biggest holding. First County Bank CT’s holdings in Johnson & Johnson were worth $1,910,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also made changes to their positions in JNJ. Meridian Financial Partners LLC purchased a new stake in Johnson & Johnson during the second quarter worth about $1,626,000. Meridian Investment Counsel Inc. grew its holdings in shares of Johnson & Johnson by 19.6% in the third quarter. Meridian Investment Counsel Inc. now owns 22,629 shares of the company’s stock valued at $3,667,000 after purchasing an additional 3,710 shares in the last quarter. Sheaff Brock Investment Advisors LLC lifted its holdings in Johnson & Johnson by 137.2% during the 3rd quarter. Sheaff Brock Investment Advisors LLC now owns 43,568 shares of the company’s stock worth $7,061,000 after buying an additional 25,203 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in Johnson & Johnson by 0.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 17,639,368 shares of the company’s stock valued at $2,858,543,000 after buying an additional 102,502 shares during the period. Finally, Lmcg Investments LLC grew its stake in shares of Johnson & Johnson by 32.7% in the third quarter. Lmcg Investments LLC now owns 87,162 shares of the company’s stock worth $14,125,000 after acquiring an additional 21,471 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the transaction, the vice president now directly owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. The trade was a 22.90 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.16% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of recent research reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 16th. Wells Fargo & Company lifted their price objective on Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Royal Bank of Canada upped their target price on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 16th. Guggenheim lifted their price target on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 6th. Finally, Wolfe Research assumed coverage on shares of Johnson & Johnson in a research report on Friday, November 15th. They issued an “outperform” rating and a $190.00 price objective on the stock. Seven investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $175.94.

Johnson & Johnson Stock Up 1.8 %

Shares of NYSE JNJ opened at $155.79 on Friday. The stock has a market cap of $375.08 billion, a PE ratio of 22.55, a price-to-earnings-growth ratio of 2.72 and a beta of 0.53. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85. The business has a 50-day moving average price of $160.41 and a 200 day moving average price of $156.17. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. The business had revenue of $22.47 billion for the quarter, compared to analysts’ expectations of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The company’s quarterly revenue was up 5.2% on a year-over-year basis. During the same period in the previous year, the company posted $2.66 EPS. Equities research analysts forecast that Johnson & Johnson will post 9.93 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.18%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio is currently 71.78%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.